/ Pipeline
Beyond ALS: A Platform
for Neuroimmune Disorders
Post-ALS expansion will target:
- Selected cancers
- Parkinson’s Disease
- Other neurodegenerative diseases
All conditions share common inflammatory pathways that SELanetx™ can regulate via immune reprogramming.